Skip to main content
. 2022 Nov 24;23:1011. doi: 10.1186/s12891-022-05987-2

Table 1.

Anthropometric data, biochemistry, fractures and agents that affect bone metabolism for patients treated with teriparatide at the start of the treatment, for all women (n = 40) and for all women with 10 years follow-up (n = 20). The p-value shows comparison between study start and 10 years’ follow-up in the 20 women who fulfilled the entire teriparatide study

Anthropometric and treatment data
Mean (Standard Deviation)
Teriparatide at treatment start
n = 40
Teriparatide at treatment start
n = 20
Teriparatide 10 years after treatment start
n = 20
p-value
10 years versus start
n = 20
Age (years) 69.5 (10.9) 64.2 (12.3) 74.7 (12.5) < 0.001
Height (m) 1.59 (0.86) 1.60 (0.91) 1.58 (0.11) 0.003
Body weight (kg) 60.3 (10.2) 61.6 (11.7) 60.8 (16.2) 0.62
BMI (kg/m2) 24.0 (3.7) 23.7 (4.1) 24.3 (5.0) 0.25
Waist (cm) 86.8 (10.5) 86.7 (9.3) 90.6 (14.7) 0.14
Hip (cm) 101.5 (7.6) 102.2 (9.5) 100.6 (13.5) 0.55
Waist to hip ratio 0.86 (0.09) 0.87 (0.07) 0.91 (0.10) 0.51
BMD femoral neck (g/cm2) 0.68 (0.15) 0.68 (0.17) 0.69 (0.20) 0.97
BMD lumbar spine(g/cm2) 0.89 (0.20) 0.88 (0.22) 0.93 (0.25) 0.62
T-score femoral neck −2.60 (1.16) −2.58 (1.30) −2.59 (1.63) 0.62
T-score lumbar spine −2.61 (1.69) −2.60 (1.82) − 2.25 (2.09) 0.39
S-Osteocalcin (μg/L) 12.8 (6.3) 14.9 (6.8) 21.6 (26.0) 0.55
S-Ca total (mmol/L) 2.32 (0.09) 2.29 (0.06) 2.37 (0.11) 0.02
S-Ca ion (mmol/L) 1.23 (0.07) 1.20 (0.08) 1.25 (0.04) 0.26
S-PTH (pmol/L) 4.3 (1.0) 4.1 (0.7) 3.8 (1.4) 0.13
Subjects with fractures, n (%) 40 (100%) 20 (100%) 7 (35.0%) < 0.001
Cortisone treatment, n (%) 10 (25.0%) 4 (20.0%) 4 (20.0%) 1.00
Estrogen replacement, n (%) 8 (20.0%) 4 (20.0%) 2 (10.0%) 0.66
Bone specific agent, n (%) 23 (57.5%) 13 (65.0%) 16 (80.0%) 0.48

BMI body mass index, BMD Bone Mineral Density, S-Ca total total serum calcium, S-Ca ion serum ionized calcium, S-PTH serum parathyroid hormone